[
    [
        {
            "time": "2018-06-17",
            "original_text": "Validea's Top Five Healthcare Stocks Based On John Neff",
            "features": {
                "keywords": [
                    "healthcare stocks",
                    "John Neff",
                    "investment strategy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Validea's Top Five Healthcare Stocks Based On John Neff",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-17",
            "original_text": "Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "patent cliff",
                    "billion"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 9,
                "Duration": 10,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]